Login to myESAIC Membership


The ESAIC is dedicated to supporting professionals in anaesthesiology and intensive care by serving as the hub for development and dissemination of valuable educational, scientific, research, and networking resources.



The ESAIC hosts the Euroanaesthesia and Focus Meeting congresses that serve as platforms for cutting-edge science and innovation in the field. These events bring together experts, foster networking, and facilitate knowledge exchange in anaesthesiology, intensive care, pain management, and perioperative medicine. Euroanaesthesia is one of the world’s largest and most influential scientific congresses for anaesthesia professionals. Held annually throughout Europe, our congress is a contemporary event geared towards education, knowledge exchange and innovation in anaesthesia, intensive care, pain and perioperative medicine, as well as a platform for immense international visibility for scientific research.


Professional Growth

The ESAIC's mission is to foster and provide exceptional training and educational opportunities. The ESAIC ensures the provision of robust and standardised examination and certification systems to support the professional development of anaesthesiologists and to ensure outstanding future doctors in the field of anaesthesiology and intensive care.



The ESAIC aims to advance patient outcomes and contribute to the progress of anaesthesiology and intensive care evidence-based practice through research. The ESAIC Clinical Trial Network (CTN), the Academic Contract Research Organisation (A-CRO), the Research Groups and Grants all contribute to the knowledge and clinical advances in the peri-operative setting.

Learn more about the ESAIC Clinical Trial Network (CTN) and the associated studies.


EU Projects

The ESAIC is actively involved as a consortium member in numerous EU funded projects. Together with healthcare leaders and practitioners, the ESAIC's involvement as an EU project partner is another way that it is improving patient outcomes and ensuring the best care for every patient.


Patient Safety

The ESAIC aims to promote the professional role of anaesthesiologists and intensive care physicians and enhance perioperative patient outcomes by focusing on quality of care and patient safety strategies. The Society is committed to implementing the Helsinki Declaration and leading patient safety projects.



To ESAIC is committed to implementing the Glasgow Declaration and drive initiatives towards greater environmental sustainability across anaesthesiology and intensive care in Europe.



The ESAIC works in collaboration with industry, national societies, and specialist societies to promote advancements in anaesthesia and intensive care. The Industry Partnership offers visibility and engagement opportunities for industry participants with ESAIC members, facilitating understanding of specific needs in anaesthesiology and in intensive care. This partnership provides resources for education and avenues for collaborative projects enhancing science, education, and patient safety. The Specialist Societies contribute to high-quality educational opportunities for European anaesthesiologists and intensivists, fostering discussion and sharing, while the National Societies, through NASC, maintain standards, promote events and courses, and facilitate connections. All partnerships collectively drive dialogue, learning, and growth in the anaesthesiology and intensive care sector.



Guidelines play a crucial role in delivering evidence-based recommendations to healthcare professionals. Within the fields of anaesthesia and intensive care, guidelines are instrumental in standardizing clinical practices and enhancing patient outcomes. For many years, the ESAIC has served as a pivotal platform for facilitating continuous advancements, improving care standards and harmonising clinical management practices across Europe.



With over 40 years of publication history, the EJA (European Journal of Anaesthesiology) has established itself as a highly respected and influential journal in its field. It covers a wide range of topics related to anaesthesiology and intensive care medicine, including perioperative medicine, pain management, critical care, resuscitation, and patient safety.



Becoming a member of ESAIC implies becoming a part of a vibrant community of nearly 8,000 professionals who exchange best practices and stay updated on the latest developments in anaesthesiology, intensive care and perioperative medicine. ESAIC membership equips you with the tools and resources necessary to enhance your daily professional routine, nurture your career growth, and play an active role in advancing anaesthesiology, intensive care and perioperative medicine.

Membership opportunities
at the ESAIC

Newsletter 2021

Newsletter November 2021: High flow nasal oxygen: A rising star waiting to be discovered

Cheah Kean Seng,MD
Department of Anaesthesia & Intensive Care
Tallaght University Hospital

High flow nasal oxygen therapy (HFNO2) is gaining popularity of late and rapidly recognised as new oxygen therapy in the treatment of respiratory failure, and the fame exploded exponentially after the COVID-19 pandemic.

HFNO2 was initially invented for neonates to provide continuous positive airway pressure (CPAP). The conventional tight-fitting face mask makes neonates vulnerable to pressure sores, so the design of HFNO2 is to provide CPAP via a specially designed cannula that fits in those tiny little nostrils without compromising blood flow to the skin. HFNO2 consists of a nasal cannula, an air/oxygen blender and a humidication device. The warm humidified air helps to maintain normal mucociliary function along the respiratory epithelium and prevent airway dryness. It can provide FiO2 close to 1.0 to improve the oxygen reserve and reduce anatomical dead space. The CPAP effects improve end-expiratory lung volume and alveolar recruitment. It allows modification of Fi02 0.21-1.0 and flow of 40-60 L/min.

Whilst strong evidence of benefits in paediatric populations exist, there is still a lot of debate going on for adults. Until now there are still no clear guidelines on the indications, but it has been tested in a few circumstances below. It is versatile, user-friendly and can be operated by anyone even when not ventilator trained.


Hypoxaemic respiratory failure

Several studies have shown that HFNO is superior to conventional forms of oxygen administration in improving oxygenation and patient comfort while reducing respiratory rate, dyspnoea and clinical signs of respiratory distress. Sztrymf et al. noticed 70% of patients from a study escaped intubation with HFNO2, and showed significant improvement in partial pressure oxygen, dyspnoea and respiratory rate¹. In FLORALI trial, the use of HFNO2 did not affect the intubation rate, (except in patients with PF ratio <200mmHg) but resulted in lower mortality at 90 days². It may benefit mild ARDS, although only based on data from observational studies.³. Since the outbreak of the COVID-19 pandemic, its role has been heavily investigated and evidence so far is promising. In the resource-constrained settings where health care capacity is struggling to meet the demand in ventilators and ICU beds, HFNO2 helps to prevent worsening oxygenation, decreasing the need for intubation in patients and it reduced the length of hospital stay in COVID-19 patients⁴.

Airway management

Preoxygenation is an important step prior to intubation for denitrogenation. Commonly the mask must be removed for intubation, but with HFNO2 it can be kept on the patient without interruption to intubate. It maintains oxygen insufflation into the lungs by diffusion during apnoea. This longer period of apnoea is essential in a patient at risk of early desaturation from low oxygen reserve (obese, obstetric and bariatric patient). It has been used during fibreoptic intubation as it delivers FiO2 near to 1.0 through nasal cannula and allows the passage of fibreoptic scope.

Post extubation/post-operative oxygen support

HFNO2 has a role as pre-emptive therapy in patients with a high risk of extubation failure. Not only it is non-inferior to NIV in terms of reintubation rate and mortality but patients have better tolerance⁵. Its use in post-operation is still inconclusive after a study on post-cardiothoracic and abdominal surgery⁶.

Other patient group

Lately, the use of HFNO2 was tested beyond theatre and ICU, such as oxygen support in bronchoscopy. During bronchoscopy, ventilation/perfusion mismatch can happen. The arterial tension is expected to drop 20mmHg and the most critical reduction usually occurs during lavage. There is also a tendency to develop atelectasis due to suction. High FiO2 and PEEP from HFNO2 help to counteract this mechanism. Obese patients are particularly at risk of desaturation and hypoxaemic from sedation, so HFNO2 can solve this problem too. Its evidence in palliative, immuno-suppression, chronic obstructive airway disease and pulmonary oedema is still lacking.


The contraindications are somewhat similar to NIV, except it is an open system so the sealed interface is not necessary. It might be a solution for those who are claustrophobic. Patients with a low consciousness, facial trauma or facial malformations should not be given it. It should also not be used in haemodynamically unstable patients.

Patient selection is important for the successful outcome of HFNO2. Inappropriate perseverance to it will cause a delay in intubation and poor outcome. When giving HFNO2 to patients, clinicians must remember that this is a narrow window period for them to decide if treatment is successful, or needs intubation regardless. There is still no consensus on what clinical parameter we can use as a guide to conclude that the patient will not benefit further and proceed to plan B (invasive mechanical ventilation). ROX score (ratio of SpO2/FIO2 to respiratory rate) is seen as a useful indicator. Quoted from the European Respiratory Journal, a ROX scores greater or equal to 4.88 at 12 hours predicts a lower risk of progressing to mechanical ventilation⁷. Apart from that, APACHE 2 and degree of PF ratio improvement seems to be a promising predictor as well⁸. The concern regarding the association of HFNO2 with increased aerosolisation is another topic of debate. Jie Li et al refute this hypothesis as they found no increase in contamination from air sampling and sample plates inside the room of pneumonia patients in ICU.

Future research:

The role of HFNO2 is in its infancy period and only more trials can tell how far it can go. In the population cohort, we should narrow the focus to comorbid patients (chronic lung disease, cardiac disease and morbidly obese) as it helps to avoid risks of intubation and invasive ventilation. In palliative care, is there any role for HFNO2 as symptomatic support in terminally ill patients? Is it more cost-effective assuming it can be administered at home? We need a strong level of recommendation on the threshold of ROX score and time of scoring, to decide on timing we should make the call to stop and proceed to intubate. We are also lacking evidence on optimal flow and FiO2 in clinical settings. A perfect example from a recently published study in patients during cardiac electronic device insertion¹⁰. This study compared the difference in the patient’s carbon dioxide (CO2) level between HFNO2 and facemask oxygen during the procedure. There was no difference in CO2 level and a surprisingly higher incidence of desaturation seen in the HFNO2 group. One of the explanations could be due to the suboptimal gas flow of or FiO2 during the procedure.

In general, HFNO2 is an exciting prospect. No one has an idea of how far it can go until we get more evidence from further studies. It has the potential to revolutionise oxygen therapy in future. It is a rising star waiting to be discovered.



  1. Sztrymf B, Messika J, Bertrand F et al.. Intensive Care Med. 2011; 37:1780. doi: 10.1007/s00134-011-2354-6. Epub 2011 Sep 27. PMID: 21946925.
  2. Frat JP, Thille AW, Mercat A et al; FLORALI Study Group; REVA Network. N Engl J Med. 2015; 372:2185.
  3. Demoule A, Hill N, Navalesi P. Intensive Care Med. 2016; 42(5):768. doi: 10.1007/s00134-016-4323-6. Epub 2016 Mar 23. PMID: 27007110.
  4. Mellado-Artigas, R., Ferreyro, B.L. et al. Crit Care 2021;25: 58 .
  5. Hernández G, Vaquero C, Colinas L et al.. JAMA. 2016; 316:1565.
  6. Futier E, Paugam-Burtz C, Godet T et al; Intensive Care Med. 2016 ; 42:1888.
  7. Cysneiros A, Organista D, Machado D et al. European Respiratory Journal 2020 ;56: 3446.
  8. Shang X, Wang Y.. Ther Adv Respir Dis. 2021 ; 15:17534666211004235.
  9. Jie Li, James B. Fink, Stephan Ehrmann; Eur Resp J 2020;56:2003136
  10. Conway A, Collins P, Chang K et al. l. Eur J Anaesthesiol. 2021 ; 38:839. doi: 10.1097/EJA.0000000000001458. PMID: 33492872.